Sermorelin
Geref · GRF 1-29
Popular for:Growth hormone stimulation, sleep quality, anti-aging
21
Total Studies
14
Human Studies
Approved
Evidence Level
Not Approved
FDA Status
Overview
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. It was FDA-approved in 1997 as Geref for diagnostic evaluation of pituitary function and was used clinically for growth hormone deficiency in children.
Although the branded product was discontinued in 2008 due to manufacturing issues (not safety concerns), Sermorelin continues to be widely compounded and studied. It stimulates the pituitary to produce and release its own growth hormone, preserving the natural feedback loop.
Mechanism of Action
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and secretion of endogenous growth hormone. Unlike exogenous HGH administration, Sermorelin preserves the hypothalamic-pituitary feedback loop, meaning the body maintains natural regulatory control over GH levels.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
21
Total Studies
14
Human Studies
Previously FDA-approved (Geref, 1997). Branded product discontinued 2008 (manufacturing, not safety). Widely compounded. Potential Category 1 reinstatement under RFK announcement.
Key Studies / PubMed References
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Animal StudyUçaktürk E, Nemutlu E · Journal of pharmaceutical and biomedical analysis · 2026
PMID: 41138283Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
ReviewRahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
PMID: 41490200A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
ReviewCoutinho LFD, DE Oliveira Neves LF, Camilo RP · The Journal of sports medicine and physical fitness · 2026
PMID: 41880199Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Animal StudyThomas A, Walpurgis K, Thevis M · Journal of mass spectrometry : JMS · 2024
PMID: 38197510In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.
ReviewGonzález-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, et al. · Biomedical chromatography : BMC · 2023
PMID: 37688464Side Effects & Safety
Known Interactions
No curated interaction entry is live for Sermorelin yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Sermorelin is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.